Speech by the chairman and secretary of the conference











In the  name of God

Histiocytoses describe a diverse group of proliferative disorders involving dentritic cells and macrophages. They include a spectrum of diseases including a reactive inflammatory accumulation of cells, pathologic immune activation, or neoplastic clonal proliferation.

Revision in the classification of histiocytoses is based on histology, phenotype, molecular alterations, , clinical and imaging characteristics. This revised classification system consists of 5 groups of diseases: (1) Langerhans-related, (2) cutaneous and mucocutaneous, and (3) malignant histiocytoses as well as (4) Rosai-Dorfman disease and (5) hemophagocytic lymphohistiocytosis and macrophage activation syndrome.

The broad spectrum of clinical symptoms and rarity of histiocytosis disordrers make the diagnosis difficult. The unclear nature, the heterogeneous course of the disease from an asymptomatic form to those with various clinical symptoms, the diverse prognosis and the risk of long-term complications cause these  group of disorders to remain a major challenge for medicine.

Advanced molecular technologies are resulting in new breakthroughs in understanding the pathophysiology of histiocytic disorders that are changing the field. One of  the recent advances includs  BRAF V600Emutation, responsible for activation of the MAPKinase RAS-RAF-MEK-ERK cell signaling pathway in pathologic histiocytes, is present in ~55% of LCH cases and was associated with recurrence and high-risk presentation .Also responses to BRAF inhibitors Vemurafenib, in patients with BRAF V600E-mutated LCH confirms that BRAF V600E is a driver mutation in LCH, that is  one of the most important group of histiocytosis  disorders.

Duo to   many  challenges in diagnosis  and treatment   of Histiocytosis   disorders in children   the  Department of ” Pediatric Hematology -Oncology “decided  to   held      the  “11th  international Hematlogy-Oncology meeting” as  title of “Updates in Histiocytosis  . This  meeting will be  held  by  clollaboration of many  great and scientific  authors  of “International  Histiocyte Society  “ , and    great ” internal   collegues”  .

Meeting  will be  held in  beautiful  Kish island of  Iran  for  2 days  ; 23 & 24 of NOV 2018.

It is our pleasure  to invite  all of our dear  collegues  for  participation and sharing  in this meeting and we hope  this meeting  would be   helpful   for  all of  our  dear  collegues .

Dr Gholamreza Bahoush- Dr Bibi shahin shamsian